Apr. 18, 2005 | |||||||||||||||||||||||||||||||||||||||||||||||
Advertising BioFact: |
Clinical Trials Breakfast Lecture: Under the New Regulatory Climate, May 10 - Seattle (pdf 155 kb) Fifth Annual Northwest Gene Expression Conference, May 25-27, Seattle...Sign up now! |
||||||||||||||||||||||||||||||||||||||||||||||
CEO Reading List
George Rathmann is currently a board member of ZymoGenetics Inc. and Chairman Emeritus of Amgen, Inc. He was previously Chairman of the Board of ICOS Corporation and Hyseq, Inc. He served as Chairman, President and Chief Executive Officer at Amgen from its inception in 1980 to October 1988 and Chairman from October 1988 to July 1990. Before joining Amgen, Rathmann was Vice President, Research and Development, Diagnostics Division, of Abbott Laboratories, which he had joined in 1975. Previous experience included Litton Industries, as President of Litton Medical Systems, Inc., and the 3M Company. Dr. Rathmann received his B.S. in Physical Chemistry from Northwestern University, and his Ph.D. from Princeton University in Physical Chemistry. He is a member of the National Academy of Engineering, the American Association for the Advancement of Science, the American Chemical Society, and since 1982 he has served as an Officer and Board Member of the Biotechnology Industry Organization and was Chairman from 1986-1988. He is an Officer and Board Member of the National Science and Technology Medals Foundation. He is on the Board of Trustees of the Fred Hutchinson Cancer Research Center and the Keystone Center, and is a member of the Board of Directors of PhRMA and Somatogen, Inc. Company Profile ZymoGenetics is a targeted bioinformatics-driven company dedicated to the discovery and development of novel therapeutic agents used in the treatment and prevention of human illness. George Rathmann's Suggested Reading List
We welcome your feedback and comments. |
|||||||||||||||||||||||||||||||||||||||||||||||
|